Page last updated: 2024-10-16

carbon monoxide and Hematologic Malignancies

carbon monoxide has been researched along with Hematologic Malignancies in 7 studies

Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.

Research Excerpts

ExcerptRelevanceReference
" In multivariate analysis, chronic graft-versus-host disease (relative risk, 16) and pretransplantation diffusion capacity for carbon monoxide or forced expiratory volume in the first second <80% predicted were independently associated with a late decrease in PF from baseline (relative risk, 7)."3.73Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. ( Barrett, AJ; Childs, R; Karimpour, S; Mielke, S; Montero, A; Rezvani, K; Savani, BN; Shenoy, A; Singh, A; Srinivasan, R, 2006)
" In three patients the pulmonary disorder seems to have been caused by a cell-mediated immunological side effect in the form of interstitial pneumonitis."1.32Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies. ( Anderson, P; Höglund, M; Rödjer, S, 2003)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Coffey, DG1
Pollyea, DA1
Myint, H1
Smith, C1
Gutman, JA1
Au, BK1
Gooley, TA1
Armand, P1
Fang, M1
Madtes, DK1
Sorror, ML1
Boeckh, MJ1
Gibson, CJ1
Deeg, HJ1
Storb, R1
Appelbaum, FR1
Chien, JW2
Martin, PJ1
Li Volti, G1
Tibullo, D1
Vanella, L1
Giallongo, C1
Di Raimondo, F1
Forte, S1
Di Rosa, M1
Signorelli, SS1
Barbagallo, I1
Sullivan, KM1
Anderson, P1
Höglund, M1
Rödjer, S1
van der Lee, I1
Zanen, P1
van den Bosch, JM1
Lammers, JW1
Savani, BN1
Montero, A1
Srinivasan, R1
Singh, A1
Shenoy, A1
Mielke, S1
Rezvani, K1
Karimpour, S1
Childs, R1
Barrett, AJ1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for Treatment of Bronchiolitis Obliterans Syndrome[NCT01287078]Phase 225 participants (Actual)Interventional2011-01-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Disease Progression at Baseline With Decline in FEV1 Greater Than 10%

Participants with progressive disease at baseline with decline in FEV1 greater than 10% (NCT01287078)
Timeframe: 18 weeks

InterventionParticipants (Count of Participants)
Inhaled Cyclosporine in HSCT Recipients2
Inhaled Cyclosporine in Lung Transplant Recipients0

Disease Progression at Baseline With Stablization of FEV1

Participants with progressive disease at baseline with stablization of FEV1 (NCT01287078)
Timeframe: 18 weeks

InterventionParticipants (Count of Participants)
Inhaled Cyclosporine in HSCT Recipients2
Inhaled Cyclosporine in Lung Transplant Recipients0

Disease Stability at Baseline With Stablization in FEV1 and Greater Than 25% Decline in Systemic Immunosuppression

Participants with stable disease at baseline with stablization in FEV1 and greater than 25% decline in systemic immunosuppression (NCT01287078)
Timeframe: 18 weeks

InterventionParticipants (Count of Participants)
Inhaled Cyclosporine in HSCT Recipients3
Inhaled Cyclosporine in Lung Transplant Recipients0

Overall Non-response to Treatment

Participants who did not respond to treatment with cyclosporine inhalation solution (CIS) (NCT01287078)
Timeframe: 18 weeks

InterventionParticipants (Count of Participants)
Inhaled Cyclosporine in HSCT Recipients7
Inhaled Cyclosporine in Lung Transplant Recipients2

Overall Response to Treatment Based on Positive Response to Cyclosporine Inhalation Solution (CIS)

Participants who responded to treatment with cyclosporine inhalation solution (CIS) (NCT01287078)
Timeframe: 18 weeks

InterventionParticipants (Count of Participants)
Inhaled Cyclosporine in HSCT Recipients9
Inhaled Cyclosporine in Lung Transplant Recipients0

Stable Disease at Baseline With Stablization of FEV1 and no Change or Increase in Systemic Immunosuppresion

Participants with stable disease at baseline with stablization of FEV1 and no change or increase in systemic immunosuppresion (NCT01287078)
Timeframe: 18 weeks

InterventionParticipants (Count of Participants)
Inhaled Cyclosporine in HSCT Recipients4
Inhaled Cyclosporine in Lung Transplant Recipients2

Stable or Progressive Disease at Baseline With Greater Than 20% of Decline in FEV1

Participants with stable or progressive disease at baseline with greater than 20% of decline in FEV1 (NCT01287078)
Timeframe: 18 weeks

InterventionParticipants (Count of Participants)
Inhaled Cyclosporine in HSCT Recipients1
Inhaled Cyclosporine in Lung Transplant Recipients0

Stable or Progressive Disease at Baseline With Improvement of FEV1

Participants with stable or progressive disease at baseline with improvement of FEV1 (NCT01287078)
Timeframe: 18 weeks

InterventionParticipants (Count of Participants)
Inhaled Cyclosporine in HSCT Recipients4
Inhaled Cyclosporine in Lung Transplant Recipients0

Reviews

1 review available for carbon monoxide and Hematologic Malignancies

ArticleYear
The Heme Oxygenase System in Hematological Malignancies.
    Antioxidants & redox signaling, 2017, 08-20, Volume: 27, Issue:6

    Topics: Animals; Antineoplastic Agents; Biliverdine; Carbon Monoxide; Epigenesis, Genetic; Hematologic Neopl

2017

Trials

1 trial available for carbon monoxide and Hematologic Malignancies

ArticleYear
Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:5

    Topics: Adolescent; Adult; Alanine Transaminase; Allografts; Carbon Monoxide; Child; Creatinine; Disease-Fre

2015

Other Studies

5 other studies available for carbon monoxide and Hematologic Malignancies

ArticleYear
Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index.
    Bone marrow transplantation, 2013, Volume: 48, Issue:9

    Topics: Adult; Aged; Carbon Monoxide; Comorbidity; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Tr

2013
Carbon monoxide diffusion capacity: how low can you go for hematopoietic cell transplantation eligibility?
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:4

    Topics: Adult; Carbon Monoxide; Diffusion; Female; Guidelines as Topic; Hematologic Neoplasms; Hematopoietic

2009
Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies.
    American journal of hematology, 2003, Volume: 73, Issue:1

    Topics: Adult; Aged; Autoimmunity; Carbon Monoxide; Female; Hematologic Neoplasms; Humans; Immunity, Cellula

2003
Pattern of diffusion disturbance related to clinical diagnosis: The K(CO) has no diagnostic value next to the DL(CO).
    Respiratory medicine, 2006, Volume: 100, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Blood-Air Barrier; Carbon Monoxide; Diffusio

2006
Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:12

    Topics: Adolescent; Adult; Carbon Monoxide; Child; Chronic Disease; Comorbidity; Disease Progression; Female

2006